Plerixafor Mobilization Data in Patients with Hemoglobin Variants
نویسندگان
چکیده
منابع مشابه
Plerixafor for autologous CD34+ cell mobilization
High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34(+) cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis b...
متن کاملPlerixafor use for peripheral blood stem cell mobilization in Korea
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Hematologic Malignancy Branch, National Cancer Center, Ilsan, Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea...
متن کاملHemoglobin Variants in Type 2 Diabetes Patients
Measurement of HbA1c levels in diabetic patients is an established procedure for evaluating long-term control of diabetes. Despite its usefulness, conditions that effect hemoglobin concentration, such as hemoglobinopathies give rise to inappropriate HbA1c values. Since information about hemoglobinopathies in the diabetic population in Sri Lanka is limited, a prospective cross-sectional study wa...
متن کاملPlerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.
BACKGROUND High-dose chemotherapy with autologous stem-cell transplantation (asct) is an accepted part of standard therapy for patients with hematologic malignancies. Usually, stem-cell mobilization uses granulocyte colony-stimulating factor (g-csf); however, some patients are not able to be mobilized with chemotherapy and g-csf, and such patients could be at higher risk of failing mobilization...
متن کاملEconomic evaluation of plerixafor for stem cell mobilization.
INTRODUCTION Autologous peripheral stem cell transplantation (ASCT) with high-dose chemotherapy is a preferred treatment for relapsed non- Hodgkin lymphoma (NHL) patients. Estimated failure rates with current stem cell mobilization (SCM) regimens are 5% to 30%. Granulocyte colony-stimulating factor (G-CSF) with plerixafor (G P) is superior to G-CSF alone for SCM in heavily pretreated NHL patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biology of Blood and Marrow Transplantation
سال: 2017
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2016.12.299